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Introduction: The use of Cf-252 isotope in the
Lithuanian Cancer Center (LCG) was initiated in
late 1987. Low specific activity (0.3-0.7I1g) Cf-
252 needles and flexible (1-5 I1g) sources have
been successfully employed for treatment of
many different lesions (gynecology, head and
neck, skin etc.). A high activity (O.3-1.5mg)
remote afterloaded source has been mainly
used for treatment of advanced gynecological
and rectum cancers.
Material and methods: Treatment planning for
interstitial brachytherapy with Cf-252 sources.
Two types of interstitial sources are available
from the vendor (Russia). Technical
characteristics of these sources are presented
elsewhere. Calculation of gamma and neutron
absorbed dose distribution in tissue around
needle and seed of flexible assembly were
performed by Vtiurin at al. using Monte Carlo
simulation. For the last two decades a number
of investigators focused their effort on identifying
RBE of Cf-252 for different cell cultures and
tissues. Riabuchin at al. l1 have collected a
considerable amount of the radiobiological data,
plotted it against combined dose rate of gamma
and neutron components and fit this data with
following equation.
LgT) = -0.156 x LgPn+y + 0.952 (1). Reference
(prescribed) dose then is calculated in terms of
isoeffective dose which is: Diso =D n+y x T) (2).
The Paris system has been chosen for Cf-252
interstitial brachytherapy chiefly because this
system, even though primarily developed for
iridium wire, is more suitable then the
51
Manchester system. Treatment planning for
HDR remote afterloading Cf-252
brachytherapy This eqiupment has been in
use in Lithuanian Cancer Center since late 1987
and has proven to be a safe and reliable device.
The unit was design to provide isodose
distribution and treatment times somewhat
comparable to that of conventional Ir-192 and
Co-60 HDR machines. PC based "in house"
computer software has been written to calculate
two dimensional isodose distribution for a
ANET-V insertion. The Manchester system is
employed for gyneclogical treatment planning.
The plane of calculation passes through the
middle of the ovoids and intersects the tandem.
The dose is prescribed to the point A.
Result and conclusions: The treatment
planning techniques for interstitial and
intracavitary Cf-252 brachytherapy are very
similar to those for gamma emitting isotopes.
Consequently, the problems are the same. We
are using two dimensional dose matrix, however
in order to be able comprehensivery describe
and report a brachytherapy treatment, treatment
planning needs to be performed in three
dimensions. Otherwise, three dimensional
isodose surfaces surrounding an implant can be
difficult to interpret and use for a prescription
which is based on physicians prior experience.
• Calibration protocol for Cf-252 sources
needs to be developed
• Single uniform method for dose prescription
needs to be identified
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